lacosamide and Syndrome

lacosamide has been researched along with Syndrome* in 3 studies

Reviews

1 review(s) available for lacosamide and Syndrome

ArticleYear
Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:15

    Mesial temporal lobe epilepsy associated with hippocampal sclerosis (MTLE-HS) is a syndrome that is often refractory to drug treatment. The effects on specific syndromes are not currently available from the pre-marketing clinical development of new AEDs; this does not allow the prediction of whether new drugs will be more effective in the treatment of some patients.. We have reviewed all the existing literature relevant to the understanding of a potential effectiveness in MTLE-HS patients for the latest AEDs, namely brivaracetam, eslicarbazepine, lacosamide, perampanel and retigabine also including the most relevant clinical data and a brief description of their pharmacological profile. Records were identified using predefined search criteria using electronic databases (e.g., PubMed, Cochrane Library Database of Systematic Reviews). Primary peer-reviewed articles published up to the 15 June 2015 were included.. All the drugs considered have the potential to be effective in the treatment of MTLE-HS; in fact, they possess proven efficacy in animal models; currently considered valuable tools for predicting drug efficacy in TLE. Furthermore, for some of these (e.g., lacosamide and eslicarbazepine) data are already available from post-marketing studies while brivaracetam acting on SV2A like levetiracetam might have the same potential effectiveness with the possibility to be more efficacious considering its ability to inhibit voltage gated sodium channels; finally, perampanel and retigabine are very effective drugs in animal models of TLE.

    Topics: Acetamides; Anticonvulsants; Carbamates; Clinical Trials as Topic; Dibenzazepines; Epilepsy, Temporal Lobe; Hippocampus; Humans; Lacosamide; Levetiracetam; Nitriles; Phenylenediamines; Piracetam; Pyridones; Sclerosis; Syndrome

2015

Other Studies

2 other study(ies) available for lacosamide and Syndrome

ArticleYear
DRESS is a Mess: A Case of Cross Reactivity Between Lacosamide and Lamotrigine.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2021, Volume: 74, Issue:7

    Drug reaction with eosinophilia with systemic symptoms (DRESS) syndrome is a rare drug reaction often presenting with both cutaneous manifestations and potentially life-threatening internal organ involvement. The precise incidence of DRESS is still unclear as it is easily missed due to its highly variable clinical presentation. However, with an expected mortality rate of approximately 10 percent, it is important for clinicians to be familiar with pharmacologic etiologies commonly implicated in the pathogenesis. We present a case of DRESS syndrome attributed to cross-reactivity between two commonly used anticonvulsants- lacosamide and lamotrigine.

    Topics: Anticonvulsants; Eosinophilia; Humans; Lacosamide; Lamotrigine; Syndrome

2021
Paroxysmal dysarthria ataxia syndrome responds to lacosamide.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:2

    Topics: Acetamides; Adult; Anticonvulsants; Ataxia; Dysarthria; Humans; Lacosamide; Male; Syndrome; Young Adult

2015